INS and metabolic dysfunction-associated steatotic liver disease: As early as one week after alnustone administration, alnustone‐treated mice showed significantly lower blood glucose levels and improved insulin sensitivity compared with controls during the tolerance tests, suggesting benefits of alnustone against MASLD pathogenesis (Figure 1f).